EUVIMEDEUVIMED entdecken
Open Access

Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology

Alexander D Sherry iD, Pavlos Msaouel iD, Gabrielle S Kupferman iD, Timothy A Lin iD, Joseph Abi Jaoude, Ramez Kouzy iD, Zachary R McCaw iD, Ethan B Ludmir iD, Erik van Zwet iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.24.00363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Alexander D Sherry und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The primary results of phase III oncology trials may be challenging to interpret, given that results are generally based on P value thresholds. The probability of whether a treatment is beneficial, although more intuitive, is not usually provided. Here, we developed and released a user-friendly tool that calculates the probability of treatment benefit using trial summary statistics. METHODS We curated 415 phase III randomized trials enrolling 338,600 patients published between 2004 and 2020. A phase III prior probability distribution for the treatment effect was developed on the basis of a three-component zero-mean mixture distribution of the observed z-scores. Using this prior, we computed the probability of clinically meaningful benefit (hazard ratio [HR]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicRandomized Controlled Trials as TopicHumansNeoplasmsMedical OncologyTreatment OutcomeSignal-To-Noise RatioEvidence-Based Medicine

Autor:innen und Institutionen

  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Department of Radiation Oncology, Stanford University, Stanford, CA.
  • Insitro, South San Francisco, CA.

ORCID-Profile: Alexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, Timothy A Lin, Ramez Kouzy, Zachary R McCaw, Ethan B Ludmir, Erik van Zwet

Förderung

  • NCI NIH HHS

Zitieren

APA

Sherry, A. D., Msaouel, P., Kupferman, G. S., Lin, T. A., Abi Jaoude, J., Kouzy, R., McCaw, Z. R., Ludmir, E. B., & van Zwet, E. (2024). Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology. JCO Precision Oncology. https://doi.org/10.1200/po.24.00363

Vancouver

Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, et al. Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology. JCO Precision Oncology. 2024. doi:10.1200/po.24.00363

BibTeX
@article{Sherry2024,
  author = {Sherry, Alexander D and Msaouel, Pavlos and Kupferman, Gabrielle S and Lin, Timothy A and Abi Jaoude, Joseph and Kouzy, Ramez and McCaw, Zachary R and Ludmir, Ethan B and van Zwet, Erik},
  title = {Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.24.00363}
}
Kostenlos starten →